Current Pharmacological Therapies for the Management of Spondyloarthritis: Special Considerations in Older Patients

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

(2023) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI

(2023) John M. LaForge et al.   ADVANCES IN THERAPY

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

(2022) Steven R. Ytterberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

(2022) Kosuke Ebina et al.   Scientific Reports

Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features

(2022) Hugo Ribeiro et al.   BIOMEDICINE & PHARMACOTHERAPY

Treatment of axial spondyloarthritis: an update

(2022) Abhijeet Danve et al.   Nature Reviews Rheumatology

Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease

(2022) Takahiro Amano et al.   Scientific Reports

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

(2022) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

(2022) E. L. M. ter Haar et al.   DRUGS & AGING

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2022) Atul Deodhar et al.   LANCET

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

(2022) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

(2022) Augusta Ortolan et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Hematologic Malignancies in Elderly Patients With Ankylosing Spondylitis: A Cohort Study and Systematic Review

(2022) Sara Alehashemi et al.   MAYO CLINIC PROCEEDINGS

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

(2021) James Cheng-Chung Wei et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

(2021) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety of JAK-1 inhibitors

(2021) Benjamin Clarke et al.   RHEUMATOLOGY

Does age matter in Psoriatic arthritis? A narrative review

(2021) George E. Fragoulis et al.   JOURNAL OF RHEUMATOLOGY

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

(2021) Walter P Maksymowych et al.   RHEUMATOLOGY

Axial spondyloarthritis

(2021) Victoria Navarro-Compán et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

(2021) Walter P Maksymowych et al.   RHEUMATOLOGY

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis

(2021) Se Hee Kim et al.   Scientific Reports

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

(2020) Iain B McInnes et al.   LANCET

Paradoxical gastrointestinal effects of interleukin-17 blockers

(2020) Marine Fauny et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

(2020) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

The TNF/IL‐23/IL‐17 axis – head‐to‐head trials comparing different biologics in psoriasis treatment

(2020) Lisa Lynn ten Bergen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Secukinumab improves signs and symptoms of non‐radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study

(2020) Atul Deodhar et al.   Arthritis & Rheumatology

Treatment strategies in axial spondyloarthritis: what, when and how?

(2020) George E Fragoulis et al.   RHEUMATOLOGY

Characteristics of late-onset spondyloarthritis in Japan

(2019) Yushiro Endo et al.   MEDICINE

The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies

(2019) Dennis G McGonagle et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

(2019) Lykke Midtbøll Ørnbjerg et al.   ANNALS OF THE RHEUMATIC DISEASES

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   ARTHRITIS CARE & RESEARCH

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

(2018) Andreas Körber et al.   DRUGS & AGING

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

(2016) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis

(2016) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

(2016) Steven E. Nissen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)

(2015) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations

(2015) Éric Toussirot   DRUGS & AGING

Overview of biologic treatments in the elderly

(2015) Clément Lahaye et al.   JOINT BONE SPINE

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis

(2014) Johanna Callhoff et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis

(2012) Ejaz Pathan et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

Late-Onset Ankylosing Spondylitis and Spondylarthritis

(2010) Éric Toussirot   DRUGS & AGING

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES